232 related articles for article (PubMed ID: 18751744)
21. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection.
Rutkowski P; Dębiec-Rychter M; Nowecki Z; Michej W; Symonides M; Ptaszynski K; Ruka W
J Eur Acad Dermatol Venereol; 2011 Mar; 25(3):264-70. PubMed ID: 20569296
[TBL] [Abstract][Full Text] [Related]
22. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532
[TBL] [Abstract][Full Text] [Related]
23. [Long-term experience with multidisciplinary therapy of twenty-six patients with dermatofibrosarcoma protuberans].
Mátrai Z; Liszkay G; Plotár V; Orosz Z; Székely J; Hitre E; Bartal A; Langmár Z; Bocs K; Rényi Vámos F; Sávolt A; Tóth L
Orv Hetil; 2009 Oct; 150(41):1894-902. PubMed ID: 19801356
[TBL] [Abstract][Full Text] [Related]
24. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.
Rutkowski P; Van Glabbeke M; Rankin CJ; Ruka W; Rubin BP; Debiec-Rychter M; Lazar A; Gelderblom H; Sciot R; Lopez-Terrada D; Hohenberger P; van Oosterom AT; Schuetze SM; ;
J Clin Oncol; 2010 Apr; 28(10):1772-9. PubMed ID: 20194851
[TBL] [Abstract][Full Text] [Related]
25. Dermatofibrosarcoma protuberans - the use of neoadjuvant imatinib for treatment of an uncommon breast malignancy: a case report.
McGee MW; Boukhar SA; Monga V; Weigel R; Phadke SD
J Med Case Rep; 2019 Dec; 13(1):374. PubMed ID: 31852518
[TBL] [Abstract][Full Text] [Related]
26. Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP).
Gooskens SL; Oranje AP; van Adrichem LN; de Waard-van der Spek FB; den Hollander JC; van de Ven CP; van den Heuvel-Eibrink MM
Pediatr Blood Cancer; 2010 Aug; 55(2):369-73. PubMed ID: 20582941
[TBL] [Abstract][Full Text] [Related]
27. [Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate].
Zhu JH; Li QW; Xiao WH; Sun JZ; Wang RL; Lu JY
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):470-2. PubMed ID: 21875491
[TBL] [Abstract][Full Text] [Related]
28. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.
Stacchiotti S; Pedeutour F; Negri T; Conca E; Marrari A; Palassini E; Collini P; Keslair F; Morosi C; Gronchi A; Pilotti S; Casali PG
Int J Cancer; 2011 Oct; 129(7):1761-72. PubMed ID: 21128251
[TBL] [Abstract][Full Text] [Related]
29. Genetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencing.
Hong JY; Liu X; Mao M; Li M; Choi DI; Kang SW; Lee J; La Choi Y
PLoS One; 2013; 8(7):e69752. PubMed ID: 23922791
[TBL] [Abstract][Full Text] [Related]
30. Molecular targeting of dermatofibrosarcoma protuberans: a new approach to a surgical disease.
McArthur GA
J Natl Compr Canc Netw; 2007 May; 5(5):557-62. PubMed ID: 17509258
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of metastatic fibrosarcomatous dermatofibrosarcoma protuberans with imatinib mesylate.
Kambayashi Y; Kasahara Y; Ohuchi K; Amagai R; Hashimoto A; Asano Y; Fujimura T
Dermatol Ther; 2022 Oct; 35(10):e15736. PubMed ID: 35898161
[TBL] [Abstract][Full Text] [Related]
32. Imatinib mesylate treatment for a Chinese patient with metastatic and recurrent dermatofibrosarcoma protuberans: is sustained partial remission possible?
Wang C; Luo Z; Zheng B; Chen Y; Cao X; Wang J; Zhang R; Shi Y
Eur J Cancer Prev; 2012 Nov; 21(6):585-7. PubMed ID: 23014697
[No Abstract] [Full Text] [Related]
33. Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate.
Thomison J; McCarter M; McClain D; Golitz LE; Goldenberg G
J Cutan Pathol; 2008 Nov; 35(11):1003-6. PubMed ID: 18544062
[TBL] [Abstract][Full Text] [Related]
34. Intracranial recurrence of the scalp dermatofibrosarcoma.
Kim SD; Park JY; Choi WS; Kim SH; Lim DJ; Chung HS
Clin Neurol Neurosurg; 2007 Feb; 109(2):172-5. PubMed ID: 16757109
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of Imatinib Mesylate Treatment in a Patient with Dermatofibrosarcoma Protuberans with Pulmonary and Pancreatic Metastases.
Tatai T; Gomi D; Fukushima T; Kobayashi T; Sekiguchi N; Sakamoto A; Sasaki S; Koizumi T; Sano K
Intern Med; 2016; 55(17):2507-11. PubMed ID: 27580559
[TBL] [Abstract][Full Text] [Related]
36. Targeted therapy for dermatofibrosarcoma protuberans.
Abrams TA; Schuetze SM
Curr Oncol Rep; 2006 Jul; 8(4):291-6. PubMed ID: 17254529
[TBL] [Abstract][Full Text] [Related]
37. Dermatofibrosarcoma protuberans: clinical series, national Danish incidence data and suggested guidelines.
Akram J; Wooler G; Lock-Andersen J
J Plast Surg Hand Surg; 2014 Feb; 48(1):67-73. PubMed ID: 23837507
[TBL] [Abstract][Full Text] [Related]
38. Current treatment options for dermatofibrosarcoma protuberans.
Rutkowski P; Debiec-Rychter M
Expert Rev Anticancer Ther; 2015; 15(8):901-9. PubMed ID: 26027711
[TBL] [Abstract][Full Text] [Related]
39. Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor.
Sawyers CL
J Clin Oncol; 2002 Sep; 20(17):3568-9. PubMed ID: 12202652
[No Abstract] [Full Text] [Related]
40. Dermatofibrosarcoma protuberans: a partial response to imatinib therapy.
Mehrany K; Swanson NA; Heinrich MC; Weenig RH; Lee KK; White CR; Devere TS
Dermatol Surg; 2006 Mar; 32(3):456-9. PubMed ID: 16640697
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]